Overview

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
Apotex Inc.
Treatments:
Aspirin